Análise opcional do produto
Com a sua autorização, usamos análises limitadas e respeitadoras da privacidade para perceber que percursos de investigação funcionam. Não usamos rastreadores publicitários nem gravação de sessões. Pode alterar esta escolha nas Preferências. Leia a Política de Privacidade.
Regeneron Pharmaceuticals Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $74.9B | |
|---|---|---|
| P/E (forward) | 13.3x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | — | $12.17B | $13.12B | $14.20B | $14.34B | +5.6% |
| Gross profit | — | $10.61B | $11.30B | $12.23B | $12.24B | +4.9% |
| Operating income | — | $4.92B | $4.27B | $4.84B | $5.27B | +2.4% |
| Net income | — | $4.34B | $3.95B | $4.41B | $4.50B | +1.3% |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | -12.9% |
| EBITDA | — | $5.26B | $4.69B | $5.32B | $5.82B | +3.4% |
| R&D | — | $3.85B | $4.63B | $5.23B | $5.85B | +15.0% |
| SG&A | — | $2.12B | $2.63B | $2.95B | $2.70B | +8.5% |
Recent company headlines from major financial publishers.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.6% | $1,545 | $1,793 | $2,117 | $2,117 | $2,117 |
| 6.6% | $1,210 | $1,357 | $1,545 | $1,793 | $2,117 |
| 7.6% | $994 | $1,091 | $1,210 | $1,357 | $1,545 |
| 8.6% | $844 | $913 | $994 | $1,091 | $1,210 |
| 9.6% | $733 | $784 | $844 | $913 | $994 |
Upcoming earnings date and setup when available.
A classificação que a edição de pesquisa publicada em cada mês trazia. Uma classificação compara o preço na data da análise com o valor justo; não é um registro de se a avaliação se confirmou.
| Ano | jan. | fev. | mar. | abr. | mai. | jun. | jul. | ago. | set. | out. | nov. | dez. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
